Access to Pediatric-Friendly Formulations at the Time of Pediatric Labeling and After Marketing
Inadequate PF formulation development and lack of sustained accessibility represent barriers to safe and appropriate pharmacotherapy for children. Key stakeholders should collaborate to improve medication options for pediatric patients.
Authors
- Susan M. Abdel‐Rahman (ORCID: https://orcid.org/0000-0002-5815-2029)
- Debbie Avant
- Gilbert J. Burckart (ORCID: https://orcid.org/0000-0003-2005-9301)
Institutions
- United States Food and Drug Administration (US)
- Center for Drug Evaluation and Research (US)
Publication Details
- Journal
- PEDIATRICS
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1542/peds.2025-073604
- Citations
- 2
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 6.99